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Purpose: To describe a modification technique using the low-profile Cook Zenith 25 
Alpha™ thoracic stent graft, and addition of a preloaded wire system, for urgent repair of 26 
pararenal (PRA) and thoracoabdominal (TAAA) aortic aneurysms.  27 
Methods: We analyzed 20 consecutive patients who underwent urgent physician 28 
modified endograft (PMEG) repair of PRA and TAAA at two institutions. The low-29 
profile Cook Zenith Alpha™ Thoracic stent graft was modified in according with each 30 
specific patient anatomic characteristics. Endpoints were technical success, 30-day 31 
mortality and major adverse events (MAEs).  32 
Results: Technical success was achieved in all patients (100%). A total of 76 renal-33 
mesenteric arteries were incorporated by fenestrations (70%) or directional branches 34 
(30%) with an average of 3.7±0.6 vessels per patient. There were six different types of 35 
stent configuration. The most common design consisted of four fenestrations (nine 36 
patients, 45%). The average of modification time was 110±27 minutes. Total procedure 37 
time (including the time for open component) was 242±75 minutes.  There was no death 38 
within the first 30-day or hospital stay. MAEs occurred in 10 patients (50%). The most 39 
common MAEs were acute kidney injury (by RIFLE crite a) in six patients (30%), EBL 40 
>1 L and respiratory failure requiring reintubation in two patients (10%) each, paraplegia 41 
and ischemic colitis in one patient (5%) each. One patient (5%) required temporary, new-42 
onset dialysis.  43 
Conclusion: PMEG using low – profile Zenith Alpha™ thoracic stent graft was safe with 44 
no early mortality and acceptable early morbidity.  45 
 46 
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Physician modified endograft (PMEG) technique provides a means for urgent 53 
total endovascular repair of pararenal (PRA) or thoac abdominal aortic aneurysms 54 
(TAAAs) in patients who cannot wait for manufactured f nestrated and branched 55 
endografts.  Previously reported PMEG techniques utilize he Zenith TX2® thoracic stent 56 
graft (Cook Medical Inc, Bloomington, Ind) as the base graft.1-4 Further refinements of 57 
the modification technique include addition of diameter reducing wire5, mini-cuffs1, 58 
directional side branches and pre-loaded wires.2  Introduced in the U.S. market in 2015, 59 
the low-profile Zenith Alpha™ (16~20 French) thoracic stent graft (Cook Medical Inc, 60 
Bloomington, Ind) has replaced the Zenith TX2® ( 0~24 French) as the main workhorse 61 
off-the-shelf thoracic stent graft at most centers.6, 7 We describe our most recent PMEG 62 
technique using the low-profile Zenith Alpha™ thoracic stent graft, incorporating the pre-63 
loaded wire system, for urgent repair of PRAs and TAAAs. 64 
 65 
Methods 66 
Patient Selection 67 
 A retrospective two-center study was undertaken. The study was approved by the 68 
Institutional Review Board at each institution.  Based on the retrospective nature of the 69 
 
study, individual patient consent for the study was ived. Both institutions have 70 
physician-sponsored investigational device exemption (PS-IDE) studies, but in one 71 
institution eight cases were performed outside the PS-IDE study and under 72 
compassionate use due to inability to meet the inclusion and exclusion criteria. Off-label 73 
nature of the procedure, as well as other treatment options were disclosed to the patients 74 
during procedural consent. From March 2016 to January 2019, 20 patients underwent 75 
urgent PMEG repair of PRA and TAAAs at two institutions. Patients with high risk for 76 
open repair and presented with large, rapidly expanding, or symptomatic aneurysms, in 77 
which the requisite time for custom manufactured devices carried a significant risk of 78 
rupture were included in the study.  PMEG repairs were not performed on patients with 79 
ruptured aneurysms presenting with hemodynamic instability.  In these patients, 80 
induction of general anesthesia or graft modification time carried significant risk of total 81 
circulatory collapse.   82 
Device design and planning 83 
Aneurysm morphology was determined by high-resolutin computed tomography 84 
angiography (CTA) and devices designed with a minimum landing zone of 25mm.  Three 85 
dimensional multi-planar as well as centerline reconstructions were performed for 86 
endograft modification planning.  Endograft modifications were designed by surgeons 87 
with extensive experience in fenestrated and branched endografting, or dedicated training 88 
in complex aortic endografting. Patients with extent I-II TAAAs underwent staged repair 89 
with prophylactic spinal drainage. The first stage repair consisted of proximal thoracic 90 
stent graft placement, and the second stage fenestrat d and branched endovascular repair 91 
using the PMEG technique. Neuromonitoring with motor evoked and sensory evoked 92 
 
potential monitoring was indicated for patients with extent I-II TAAAs at the final 93 
procedure.  Changes in the neuromonitoring triggers int aoperative maneuvers such as 94 
initiation (at 10 mmHg) or increase (down to 0-5 mmHg) of cerebrospinal fluid drainage 95 
and permissive hypertension with increments in target mean arterial pressure up to or 96 
above 90-100 mmHg. If these maneuvers do not revers the changes in neuromonitoring, 97 
pelvic circulation is restored by retracting the femoral sheaths and allowing circulation to 98 
be restored to the hypogastric arteries and lower extremities. If neuromonitoring changes 99 
persist at the end of the procedure, temporary aneurysm sac perfusion can be allowed by 100 
leaving one of the visceral branches or the contralateral gate of the bifurcated device 101 
unstented. 102 
 103 
Statistical analysis and definitions 104 
The reporting standards of the Society for Vascular Surgery were used to define 105 
stent-graft related outcomes and major adverse events (MAEs).(8, 9) Major adverse events 106 
(MAEs) were defined using a composite end point, which included 30-day or in-hospital 107 
mortality, acute kidney injury (by RIFLE criteria), new-onset dialysis, myocardial 108 
infarction, respiratory failure requiring prolonged mechanical ventilation or reintubation, 109 
paraplegia, stroke, bowel ischemia requiring surgical resection or intensive medical care, 110 
and estimated blood loss > 1L. Outcome measurements were technical success, 30 – day 111 
mortality and MAEs. The results were reported as percent for categorical variables and 112 





To illustrate our technique, we present one case in detail.  Patient 3 is a 77-year-117 
old female who presented with a new onset abdominal a d flank pain in the setting of a 118 
rapidly enlarging 7.5 cm Crawford extent II TAAA.  The patient had a type 3 aortic arch, 119 
and moderate amount of aortic mural thrombus (Figure 1).  The first stage operation 120 
consisted of a right iliofemoral bypass via a flank i cision, and the placement of a tapered 121 
Zenith Alpha™ thoracic stent graft (38 ~ 34 x 167 mm).  A prophylactic cerebrospinal 122 
drain was placed preoperatively. 123 
Modification 124 
A tapered 36 ~ 32 x 209 mm proximal component Cook Zenith Alpha™ thoracic 125 
stent graft was modified using strict sterile technique (Figure 2).  The stent graft was 126 
unsheathed and the proximal fixation barbs were removed (Figure 2A-B).  Fenestrations 127 
were created at the predetermined locations using ophthalmic cautery (Figure 2C).  Each 128 
fenestration was reinforced with double layers of Nitinol loops of an endovascular snare 129 
EnSNARE (Merit Medical, South Jordan, UT) using locking running 5-0 Ethibond 130 
(Ethicon, Cincinnati, OH) sutures (Figure 2D).  Radiopaque gold markers (Accellent, 131 
Washington, Mass) were sutured around each fenestration (Figure 2E).  The markers 132 
were also sutured at 12 and 6 o’clock of the stent graft to note the anterior and posterior 133 
position.  Diameter reducing ties were added along the posterior wall of the stent graft 134 
(Figure 2F).  All fenestrations were preloaded with 0.014-inch guidewires for the renal 135 
arteries or 0.018-inch guidewires for the mesenteric arteries (Figure 2G).  The modified 136 
stent graft was resheathed using 2-0 Silk ties and Silastic tape (Figure 2H-I, Video).  137 
Side arm branches were created by sewing 1~2cm segment of 6mm (or 8mm self-138 
 
expanding Viabahn covered stents (W.L. Gore and Associates, Flagstaff, AZ) onto 139 
cauterized orifices, using running 6-0 Gore-Tex sutures (W.L. Gore and Associates, 140 
Flagstaff, AZ) (Figure 3).   141 
 142 
Implantation 143 
Under general anesthesia, left proximal brachial artery was surgically exposed 144 
through a 3cm longitudinal incision immediately distal to the axillary hairline.  The right 145 
iliofemoral bypass graft was re-exposed in the groin.  Percutaneous left femoral access 146 
was performed with preclose technique using Proglide devices (Abbott Vascular, Santa 147 
Clara, CA).  The patient was fully heparinized.  A 12Fr x 45cm Dryseal Flex® sheath 148 
(Gore and Associates, Flagstaff, AZ) was introduced from the left brachial approach and 149 
positioned in the descending thoracic aorta.  Through-and-through brachiofemoral access 150 
was established, then a 5Fr x 90cm sheath was placed over this access. The preloaded 151 
wires were passed through the 5-Fr through-and-through sheath (Figure 4A). The 152 
modified Zenith Alpha™ stent graft was introduced over the Lunderquist wire, and 153 
advanced to the paravisceral aorta with the 5-Fr sheath.  The 5Fr sheath was removed 154 
from the brachial access.  Under the guidance of Fusion CT (GE Discovery IGS 730, GE 155 
Healthcare, Chicago, IL), the stent graft was positi ned with each fenestration in 156 
alignment with its target vessel (Figure 4B).  The stent graft was partially deployed while 157 
individual visceral and renal branches were sequentially catheterized from the brachial 158 
approach, using the preloaded wires (Figure 4C).  The branch catheterization technique 159 
using preloaded wires was previously described.(2) For the celiac axis (CA), 0.018-inch 160 
Steelcore wire was used, while 0.035-inch Amplatz and 0.035-inch Rosen wires were 161 
 
used for the superior mesenteric artery (SMA), and renals.  Following the complete target 162 
branch catheterization, the stent graft was fully deployed, and diameter-reducing wire 163 
removed.  The renal arteries were stented with 5mm x 22mm iCAST covered stents 164 
(Atrium, Merrimack, NH) (Figure 4D-E).   The CA and SMA were stented with 7mm x 165 
22mm and 7mm x 38mm iCAST, respectively (Figure 4F-G).  All branch stents were 166 
flared to 10mm across the fenestrations.  The repai was extended distally using 36mm 167 
Zenith aortic cuff (Cook Medical, Bloomington, IN).  The completion angiography 168 
showed complete aneurysm exclusion with widely patent branch stents (Figure 4H).   169 
Results 170 
Patient characteristics  171 
Mean age of our cohort was 74±8 years (73, 68 –78), and 10 patients (50%) were 172 
male (Table I). Aneurysms were classified as TAAA in 16 patients (80%; Extent I in 1, 173 
II in 6, III in 5, and IV in 4) or PRA in 4 patients (20%). Mean aneurysm diameter was 174 
74±17 mm (70, 63 – 88).  The most prevalent cardiovascul r risk factors were 175 
hypertension in 19 (95%) and prior history of cigarette smoking in 18 patients (90%).  176 
Ten patients (50%) presented with symptomatic non-ruptured or contained rupture of the 177 
aortic aneurysm.   178 
Stent-graft design 179 
There were six different types of stent configuration. The most common design, 180 
which was selected in 9 patients (45%), consisted of four fenestrations for the CA, SMA 181 
and renal arteries. Four patients had a single functioning kidney with chronic occlusion of 182 
one renal artery resulting in the incorporation of only three target vessels. A total of 74 183 
renal-mesenteric arteries were incorporated by fenestrations (70%) or directional 184 
 
branches (30%) with an average of 3.7±0.6 (4, 3 – 4) vessels per patient (Table II ). All 185 
fenestrations and directional branches were loaded with 0.018 or 0.014-inch wires.  The 186 
average modification time and length of the main device modified were 110±27 (105, 96-187 
131) minutes and 179±29 (170, 161-207) millimeters, re pectively. 188 
Procedure detail 189 
 Technical success, defined by deployment of the aortic stent-graft and all intended 190 
side branch components, was achieved in 100% of patients (Table II ). Twelve patients 191 
(60%) had prophylactic placement of cerebrospinal fluid drainage. Among eight patients 192 
that did not receive prophylactic spinal drain, aneurysm type was extent IV in four 193 
patients, pararenal in three and extent II in one. M an endovascular procedure time was 194 
166±85 minutes (118, 98 – 262) with fluoroscopy time of 74±27 minutes (72, 59 – 89), 195 
and 131±52 ml of iodinated contrast (120, 90 – 150) was used for each case. Total 196 
procedure time (including the time for open components) was 242±75 minutes (215, 192 197 
– 281).  Nine patients (45%) had the procedure in staged fashion with average of 17±29 198 
(5, 2-21) days for the second stage, completion procedure.  199 
Early outcomes 200 
 There was no death within the first 30-day or hospital stay. The mean length of 201 
hospital stay was 9±7 days (7, 5 – 11). Ten patients (50%) had major adverse events 202 
(MAEs, Table III ). The most common MAEs were acute kidney injury (by RIFLE 203 
criteria) in six patients (30%), EBL >1 L and respiratory failure requiring reintubation in 204 
two patients (10%) each, paraplegia and ischemic col tis in one patient (5%) each. One 205 
patient (5%) required temporary, new-onset dialysis. Two patients (10%) had a minor 206 
perioperative stroke (NIH Stroke Score 2). The patient with paraplegia, had four 207 
 
directional branches endovascular repair of the sympto atic non-ruptured Extent II 208 
TAAA. He woke up neurologically intact from anesthesia.  CSF drainage was open, and 209 
mean arterial pressure (MAP) was maintained > 80mmHg.  Eight hours later, patient had 210 
an acute onset sharp back pain radiating to legs and became densely paraplegic.  This 211 
never improved despite adjunctive measures.  212 
Four patients required early secondary intervention to treat one type IA endoleak 213 
and three access complications. Follow-up imaging was obtained in all patients. After 214 
mean follow-up of 5±6 (3, 1-9) months, there was no reintervention, aortic-related death 215 
or branch instability. 216 
 217 
Discussion 218 
Collective experience with fenestrated, branched stnt graft technology is well 219 
established with implantation in thousands of patients, and continues to grow at a rapid 220 
pace.  Concurrently, advances in low profile aortic s ent graft technology have been 221 
incorporated to the manufactured fenestrated and branched devices. However, 222 
customized endografts take weeks for delivery and off-the-shelf devices for complex 223 
aortic anatomy are limited. Hence, the role of PMEGs continues to exist in urgent cases 224 
without viable open surgical options.  225 
Reported outcomes by the authors regarding PMEGs have been favorable.  226 
Oderich and colleagues reported their series of 30 patients, 47% of which had TAAA.  227 
For a total of 85 fenestrations, branch stenting success was 98%, with one perioperative 228 
death.  In this study, median follow-up was 14 months, with 1-year branch patency of 229 
97% and freedom from endoleak of 88%.(10) In 2012, Starnes and colleagues described 230 
 
their initial outcomes of 47 consecutive patients with juxtarenal aneurysms treated with 231 
PMEG.11 Technical success was 98%, with a total of 82 fenestrations, and a perioperative 232 
mortality of 2%. Since then, Starnes and colleagues have published their updated mid-233 
term results now with 64 consecutive patients, 145 total fenestrations, and 4-year follow-234 
up.12 Technical success remained high at 95% and 30-day mortality of 5.1%. 235 
Complication rate was 12% including three myocardial inf rctions, one stroke, one renal 236 
failure, and four respiratory failure. Freedom from stent-graft migration and freedom 237 
from rupture or conversion to open at 12 months was 100%. Only two patients had type I 238 
or type III endoleak at 12 months. No new endoleaks have been detected in patients seen 239 
at 4-year follow-up. Sac stability or shrinkage was seen in 97.7% of patients at one year 240 
and 95.2% of patients at three years. Mean follow up was 28 months, with four 241 
aneurysm-related deaths. All four aneurysm-related deaths were within the 30-day 242 
perioperative window, while an additional eight all-cause mortalities occurred during 243 
follow-up for an overall survival of 70% at 4 years.   244 
   Recent report from a high-volume aortic center in Hamburg, Germany 245 
demonstrated similarly high technical success of PMEG even in the setting of contained 246 
rupture.13 Their cohort of 21 patients consisted of 11 TAAA, and 13 patients presenting 247 
with contained rupture.  Technical success of PMEG implantation was achieved in 100% 248 
of the patients.  Thirty-day survival was 95%.  Two cases of permanent paralysis were in 249 
patients who had intraoperative hypotension due to rupture.  There was 1 late aneurysm-250 
related death in a patient who developed an aortoenteric fistula.  At 11 months follow up, 251 
all branch stents remained patent.  This report highlights that PMEG technique remains 252 
useful even in European centers where the off-the-shelf device (t-Branch) is available on 253 
 
the market.  The authors noted that “since customized endografts take weeks for delivery 254 
and off-the-shelf devices for complex aortic anatomy are limited, the surgeon-modified 255 
stent-grafts appears to be an effective endovascular option because it facilitates an 256 
anatomically correct reconstruction.”  257 
O’Donnell and colleagues analyzed the outcomes of 1396 complex EVARs using 258 
the national Vascular Quality Initiatives database.  Complex EVARs consisted of 880 259 
FEVARs using commercially available ZFEN (Cook Medical, Bloomington, IN), 256 260 
PMEGs, and 260 chimney/snorkel EVARS.  Compared to ZFEN and chimney/snorkel 261 
EVARs, PMEGs were utilized to treat more extensive an urysms, incorporating more 262 
branch vessels (mean: 3.3±0.8 arteries vs. 2.5±0.6 ZFEN, and 1.9±0.9 chimney/snorkels) 263 
involving more celiac and SMA.  However, PMEG had the lowest unadjusted 264 
perioperative death rate (2.7%), compared to ZFEN (3.4%) and chimney/snorkel (6.1%).  265 
Stroke rates after PMEG (0.9%) and ZFEN (0.8%) were similar, while chimney/snorkel 266 
EVARs had significantly higher stroke rates (3.3%, p=.03).  This study reflects that 1) 267 
PMEGs play a significant role in the real-world practice of complex EVARs in the 268 
United States, and 2) short-term results achieved by PMEG are similar to the excellent 269 
results achieved by ZFEN, and superior to snorkel/chimney EVARs.14     270 
Since the published PMEG techniques using TX2 platform (Cook Medical, 271 
Bloomington, IN)1-4, the low-profile Zenith Alpha™ thoracic stent grafts have largely 272 
replaced the TX2 as the off-the-shelf thoracic stent graft at many centers.  True urgent 273 
and emergent cases will most commonly involve use of r adily available stent grafts.  As 274 
such, familiarity with the low-profile Zenith Alpha™ thoracic stent graft and its 275 
 
modification steps are critical components of achieving successful outcomes using 276 
PMEG technique. 277 
There are several differences in the PMEG technique using the Zenith Alpha™ 278 
thoracic stent graft, from its predecessor, TX2.  First, widely spaced Nitinol stents on the 279 
Alpha device (Figure 5), compared to much tighter stainless-steel Z stent offer more 280 
space to place the fenestrations without having to bend and relocate the stent wires 281 
(Figure 6).  Second, our approach to creating fenestrations involves efforts to reproduce 282 
the features of manufactured devices.  Every fenestration is created to be 8x8mm or 283 
smaller and reinforced with a double layer of EnSNARE (Merit Medical, South Jordan, 284 
UT) wires constructed of braided Nitinol.  The wires are secured around the fenestration 285 
by tightly spaced 5-0 Ethibond locking sutures (Figure 2B).  These steps are aimed at 286 
maximizing durable seal across the fenestrations with flared balloon expandable covered 287 
stents.  Sterile gold markers are placed in the configuration of the manufactured devices.  288 
Third, it is our preference to remove the active fixation barbs in order to facilitate 289 
intracorporeally rotation of the device.   290 
Despite of the high-risk patients (100% of patients were American Society of 291 
Anesthesiology category III or IV) in the urgent or emergent setting, our results compare 292 
favorably with the pre-existing literature.12-16  Technical success was achieved in 100% 293 
of patient with no 30-day mortality.  Preloaded wire technique on the Zenith Alpha 294 
platform facilitates successful target vessel catheterization, as evidenced by mean 295 
fluoroscopy time of 74min, contrast amount of 131ml.  This compares favorably to the 296 
largest PMEG experience previously published (fluoroscopy time: 108mins, and contrast: 297 
 
191ml).15 The rates of MAEs were acceptable with low secondary intervention.  Branch 298 
patency was 100% after mean follow-up 5±6 months with no branch instability observed. 299 
Despite these promising early results, some points f caution should be noted. 300 
Because there is no quality control and there is no oversight from industry representatives 301 
or a planning center, the technique is entirely dependent on the operator’s experience 302 
with sizing, modifications, and device implantation. Modifications that are ill planned or 303 
poorly conducted can lead to disastrous complications and are often not reported in the 304 
literature. In addition, physician modifications of an approved device automatically 305 
exempt the manufacturer from any product liability claim. Although any physician can 306 
perform these modifications, the Food and Drug Administration (FDA) and the SVS do 307 
not endorse the technique unless it is performed under an investigational study. Last, 308 
PMEGs are costly and may not be fully reimbursed if they are performed outside these 309 
investigational studies.17  310 
In conclusion, physician modified endograft technique can be applied to the low-311 
profile Zenith Alpha™ thoracic stent graft, to enable urgent total endovascular repair of 312 
thoracoabdominal and complex aortic aneurysms in patients with high risk for open 313 
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Table I. Demographics, clinical and anatomical characteristics of 20 patients treated 402 
using physician modified endograft (PMEG with Zenith Alpha™ thoracic stent graft. 403 
n= number of patients 
Overall 
n=20 (%) or mean ± SD (median, IQR) 
 
Demographics  
Age (years old) 74±8 (73, 68-78)   
Age > 80 years old 4 (20) 
Male gender 10 (50) 
Cardiovascular risk factors  
Cigarette smoking 18 (90)  
Hypertension 19 (95)  
Hypercholesterolemia 17 (85)  
Coronary Artery Disease 11 (55)  
COPD 10 (50)  
Peripheral arterial disease 5 (25)  
CKD Stage  
Stage I     2 (10) 
Stage II 8 (40) 
Stage III 8 (40) 
Stage IV 2 (10) 
CKD Stage III-IV 11 (55) 
Diabetes Mellitus 1 (5) 
Congestive Heart Failure 3 (15)  
Stroke/TIA 3 (15)  
Prior aortic repair 12 (60) 
Ascending or arch 2 (10) 
Open-Infrarenal 4 (20) 
EVAR-AAA 1 (5) 
TEVAR-1 Stg 9 (45) 
Preoperative evaluation 
 
Serum Creatinine (mg/dl) 1.2±0.5 (1.0, 0.9-1.3)  
eGFR (mL/min/1.73 m2) 61±22 (59, 49-81) 
Body Mass Index (kg/m2) 27±7 (25, 22-30) 
Risk assessment  
 
ASA Score  
Class 3 10 (50) 
Class 4 10 (50) 
Anatomical Characteristics 
 




















Aneurysm Type  
Crawford extent I  1 (5) 
Crawford extent II 6 (30) 
Crawford extent III 5 (25) 
Crawford extent IV 4 (20) 
Pararenal 4 (20) 
Post-dissection TAAA 1 (5) 
 
Table II.  Procedure detail and device design of 20 patients treated using physician modified 422 
endograft (PMEG) with Zenith Alpha™ thoracic stent graft. 423 
 
Overall 
n=20 (%) or mean ± SD (median, IQR) 
n= number patients 
General Anesthesia 20 (100) 
Status of aneurysm  
Large/rapidly expanding aortic aneurysm 10 (50) 
Symptomatic non-ruptured 9 (45) 
Contained ruptured 1 (5) 
Cerebrospinal Fluid Drainage 12 (60) 
Somatosensory evoked potential/Motor evoked potentials 14 (70) 
Preloaded wires 20 (100) 
Reducing diameter tie 20 (100) 
Brachial access 19 (95) 
Left side 17 (85) 
Right side 2 (10) 
Percutaneous femoral approach 15 (75) 
     Unilateral 11 (55) 
     Bilateral 8 (40) 
Iliac conduit 1 (5) 
Modification time (min) 110±27 (105, 96-131) 
Length of the main device modified (mm) 179±29 (170, 161-207) 
Amount of contrast used (ml) 131±52 (120, 90-150) 
Total endovascular time (min) 260±44 (271, 232-292) 
Total fluoroscopy time (min) 74±27 (72, 59-89) 
Total air kerma (mGy) 1975±1595 (1678, 707-3156) 
Dose Area Product (Gy.cm2) 233±154 (158, 134-291) 
Estimated blood loss (ml) 423±283 (350, 250-600) 
 
Hospital stay (days) 9±7 (7, 5-11) 
Technical success 20 (100) 
Device design 74 
Target vessel per patient 3.7±0.6 (4, 3-4) 
Fenestration 52 (70) 
Directional branches 22 (30) 
Celiac axis 17 (23) 
Fenestration 13 (18)  
Directional branches 4 (5) 
Superior mesenteric artery 20 (27) 
Fenestration 14 (19) 
Directional branches 6 (8) 
Right renal artery 19 (26)  
Fenestration 13 (18) 
Directional branches 6 (8) 
Left renal artery 17 (23) 
Fenestration 11 (15) 
Directional branches 6 (8) 










Table III.  Mortality and major adverse events (MAEs) < 30 days of 20 patients treated using 432 




n= number patients 
Early death 0 (0) 
Any major adverse event 10 (50) 
Estimate blood loss higher than 1000 ml 2 (10) 
Acute Kidney Injury by RIFLE criteria 6 (30) 
New-Onset Dialysis 1 (5) 
Myocardial Infarction 0 (0) 
Respiratory failure 2 (10) 
Any spinal cord injury 2 (10) 
Grading Classification  
1-2 (paraparesis) 1 (5) 
3a-c (paraplegia) 1 (5) 
Timing  
Immediate 0 (0) 
Delayed 2 (10) 
Any stroke 2 (10) 
Stroke major 0 (0) 
Stroke minor/TIA 2 (10) 
Bowel ischemia  1 (5) 
Access complication 3 (15) 










Figure 1.  Computed tomography angiography demonstrated a 7.7cm extent II 443 
thoracoabdominal aortic aneurysm (A).  The descending thoracic aorta had a moderate 444 
amount of mural thrombus (B).  The celiac artery (C) and superior mesenteric artery (D) 445 
were patent.  Increased amount of shaggy aortic mural thrombus was noted at the level of 446 
the right renal artery with moderate stenosis (E).  The left renal artery had a high-grade 447 
stenosis with calcified ostial lesion (F). By permission of Mayo Foundation for Medical 448 










Figure 2.  A tapered low profile alpha proximal component thoracic stent graft was 458 
unsheathed.  The device was modified on site by creating fenestrations for the visceral 459 
and renal arteries (A-C).  Fenestrations were reinforced with double layers of braided 460 
nitinol wires using running 5-0 Ethibond sutures (Ethicon, Cincinnati, OH) (D).  Each 461 
fenestration was marked with four gold radiopaque markers (arrows).  Longitudinal 462 
anterior markers (arrow head) and transverse posteri r markers were added (E).  463 
Diameter reducing ties were added along the posterir aspect of the endograft (F).  Each 464 
fenestration was preloaded with a 0.014 wire (G).  The device was constrained with Silk 465 
ties and silastic tape, then reloaded into the sheath r trograde (H-I ). By permission of 466 











Figure 3.  Directional branches are fashioned using 2-cm long Viabahn stent grafts (WL 476 
Gore, Flagstaff, AZ). The distal edge of the branch is positioned approximately 2 cm 477 
above the intended location of the target vessel within the same clock position. A 478 
Viabahn stent graft (A) is anastomosed end to side to the fenestration using running 5–0 479 
Gore sutures (WL Gore, Flagstaff, AZ). The distal edg  of the Viabahn branch is stitched 480 
to the fabric of the TX2 stent graft to prevent movement during re-sheathing and 481 
deployment. Radiopaque markers are placed at the proximal and distal edge of the 482 
fenestration and at the distal edge of the branch (B, black arrows). By permission of 483 







Figure 4.  Through-and-through brachiofemoral access was establi hed, then a 5Fr x 490 
90cm sheath was placed over this access.  The preloaded wires were passed through the 491 
5-Fr through-and-through sheath (A). The modified stent graft was advanced along with492 
the 5Fr brachiofemoral sheath.  The stent graft was positioned under fusion imaging 493 
guidance, and was deployed in staggered fashion (B), allowing sequential branch 494 
catheterization using the preloaded wires (C).  Following placement of branch bridging 495 
stents (D-G), and completion angiography showed patent branch stents and no endoleak 496 




















Figure 5. Distance apex to apex range (a) from 9.4mm ~ 11mm for Zenith TX2® thoracic 511 
stent graft (A), and 18.1mm ~ 18.8mm for Zenith Alpha™ thoracic stent graft (B). By 512 










Figure 6.  Stent relocation technique to accommodate fenestrations in Zenith TX2® 522 
thoracic stent graft requires bending and resuturing the Z stents (D-E). By permission of 523 






Video. Physician modified endograft (PMEG) technique using the low-profile Zenith 530 
Alpha™ thoracic stent graft. By permission of Mayo Foundation for Medical Education 531 
and Research. All rights reserved. 532 
 533 











